YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent performance snapshot Ligand Pharmaceuticals (LGND) has drawn…
Ligand Pharmaceuticals JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 20…
Ligand Pharmaceuticals JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate i…
With the tech sector coming under pressure many are looking for alternative investment areas. This pharma stock is an option worth considering. Continue Reading
As geopolitical tensions escalate and U.S. markets react to new tariff threats, investors are seeking stability amid heightened volatility. In such uncertain times, identifying stocks that may be trading below their fair value can present…
Key Insights Ligand Pharmaceuticals' estimated fair value is US$301 based on 2 Stage Free Cash Flow to Equity Current share price of US$189 suggests Ligand Pharmaceuticals is potentially 37% undervalued The US$243 analyst price target for…
Most readers would already be aware that Ligand Pharmaceuticals' (NASDAQ:LGND) stock increased significantly by 16% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on th…
Ligand Pharmaceuticals Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core…
Ligand Pharmaceuticals (LGND) shares have seen a steady climb in recent months, drawing some attention from investors interested in pharmaceutical royalty platforms. With solid gains over the past month, many are starting to analyze what i…
Ligand Pharmaceuticals reported third-quarter 2025 results, showing revenue of US$115.46 million and net income of US$117.27 million, both rising sharply from the previous year, and raised its full-year guidance for core revenue, royalties…
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the…
Orchestra BioMed Holdings, Inc. Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medt…
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) just released its third-quarter report and things are looking bullish. Statutory earnings performance was extremely strong, with revenue of US$115m beating expectations by 99% and earnings…
Ligand Pharmaceuticals Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnin…
Ligand Pharmaceuticals recently announced that CEO Todd Davis and CFO Tavo Espinoza will attend three major healthcare investor conferences in November 2025, including the UBS Global Healthcare Conference, Stifel 2025 Healthcare Conference…
Ligand Pharmaceuticals JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate i…
Ligand Pharmaceuticals JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company…
Ligand Pharmaceuticals JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:3…
Ligand Pharmaceuticals Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (…
As the U.S. stock market experiences a rebound with major indices like the S&P 500 reaching new all-time highs, investors are closely watching economic indicators amid ongoing government shutdown concerns and recent Federal Reserve interes…
In recent days, U.S. stock indexes have shown little movement as investors digest revised jobs data indicating a weaker labor market than previously thought. Amid these conditions, identifying stocks that may be trading below their fair va…
If you have been watching Ligand Pharmaceuticals (LGND), the $400 million convertible note offering completed this month might have made you sit up and pay attention. Not only did the company finalize this sizable senior unsecured notes de…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate i…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior note…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior no…
As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff concerns and economic health. In such a…
Ligand Pharmaceuticals Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earni…
Orchestra BioMed Holdings, Inc. • Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $1…
Ligand Pharmaceuticals JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company w…
Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84. Continue Reading View Comments
Small-cap stocks are positioned for gains and trading at a discount compared to their large-cap peers, Villere & Co. portfolio manager Sandy Villere tells the Market Domination team. Watch the video above to hear more from Villere about to…
Ligand Pharmaceuticals JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™…
Over the last 7 days, the United States market has remained flat, but it has risen by 12% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying undervalued stocks that have not yet caught up…
Ligand Pharmaceuticals Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled…
Channel Therapeutics Corporation The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million eq…